Bank Of New York Mellon Corp Aeglea Bio Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

$538 Trillion
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$0.29 - $0.61 $6,737 - $14,172	23,233 New	23,233 $6.74 Million
Q4 2022 Feb 14, 2023	BUY	$0.35 - $1.54 $8,131 - $35,778	23,233 New	23,233 $10,000
Q3 2022 Nov 14, 2022	SELL	$0.38 - $0.81 $723 - $1,541	-1,903 Reduced 7.57%	23,233 $12,000
Q2 2022 Aug 15, 2022	SELL	$0.5 - $2.66 $66,260 - $352,505	-132,521 Reduced 84.06%	25,136 $13,000
Q1 2022 May 11, 2022	SELL	$1.87 - $4.77 $3,023 - $7,713	-1,617 Reduced 1.02%	157,657 $362,000
Q4 2021 Feb 11, 2022	SELL	$3.5 - $8.42 $749 - $1,801	-214 Reduced 0.13%	159,274 $757,000
Q3 2021 Nov 12, 2021	BUY	$6.03 - $7.95 $72,884 - $96,091	12,087 Added 8.2%	159,488 $1.27 Million
Q2 2021 Aug 11, 2021	BUY	$6.32 - $8.38 $26,088 - $34,592	4,128 Added 2.88%	147,401 $1.03 Million
Q1 2021 May 13, 2021	SELL	$6.76 - $8.57 $50,875 - $64,497	-7,526 Reduced 4.99%	143,273 $1.13 Million
Q4 2020 Feb 09, 2021	SELL	$7.02 - $9.83 $4,134 - $5,789	-589 Reduced 0.39%	150,799 $1.19 Million
Q3 2020 Nov 12, 2020	BUY	$6.51 - $9.33 $69,351 - $99,392	10,653 Added 7.57%	151,388 $1.07 Million
Q2 2020 Aug 12, 2020	BUY	$4.01 - $11.04 $182,972 - $503,744	45,629 Added 47.98%	140,735 $1.3 Million
Q1 2020 May 06, 2020	BUY	$3.51 - $8.48 $16,718 - $40,390	4,763 Added 5.27%	95,106 $443,000
Q4 2019 Feb 14, 2020	BUY	$7.23 - $8.55 $5,292 - $6,258	732 Added 0.82%	90,343 $690,000
Q3 2019 Nov 07, 2019	SELL	$6.42 - $9.0 $37,890 - $53,118	-5,902 Reduced 6.18%	89,611 $689,000
Q2 2019 Aug 12, 2019	BUY	$6.1 - $8.78 $207,534 - $298,713	34,022 Added 55.33%	95,513 $654,000
Q1 2019 May 14, 2019	BUY	$7.6 - $9.4 $91,359 - $112,997	12,021 Added 24.3%	61,491 $495,000
Q4 2018 Feb 11, 2019	BUY	$6.51 - $10.19 $33,526 - $52,478	5,150 Added 11.62%	49,470 $371,000
Q3 2018 Nov 09, 2018	BUY	$8.24 - $11.0 $24,143 - $32,230	2,930 Added 7.08%	44,320 $0
Q2 2018 Aug 06, 2018	BUY	$7.87 - $10.89 $325,739 - $450,737	41,390 New	41,390 $438,000
Q1 2018 May 15, 2018	SELL	$5.07 - $10.9 $67,142 - $144,348	-13,243 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$4.0 - $5.98 $52,972 - $79,193	13,243	13,243 $72,000

Others Institutions Holding AGLE

# of Institutions

Shares Held

241K

Call Options Held

Put Options Held

Abingworth LLP London, X0

241K
Shares

$6.65 Million
0.04% of portfolio

View Full List

About Aeglea BioTherapeutics, Inc.

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

More about AGLE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Account